tiprankstipranks
Trending News
More News >
PRIM, S.A. (ES:PRM)
:PRM
Advertisement

PRIM, S.A. (PRM) AI Stock Analysis

Compare
0 Followers

Top Page

ES:PRM

PRIM, S.A.

(Frankfurt:PRM)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 4o)
Rating:73Outperform
Price Target:
€14.00
▲(5.26% Upside)
PRIM, S.A. benefits from a strong technical outlook and a solid financial foundation, despite challenges in profitability and cash flow. The absence of a P/E ratio limits valuation analysis, but the dividend yield offers some appeal. The stock's upward momentum and stable financial position are the most significant factors driving the score.

PRIM, S.A. (PRM) vs. iShares MSCI Spain ETF (EWP)

PRIM, S.A. Business Overview & Revenue Model

Company DescriptionPrim, S.A., through its subsidiaries, designs, manufactures, and commercializes orthopedic products for physiotherapy, thalassotherapy, hydrotherapy, rehabilitation, spa, geriatrics, and support techniques in Spain and internationally. The company offers products for neuro-trauma, cardiovascular, neuromodulation, operating rooms, endo-surgery, plastic surgery, and ENT. It also engages in management of wellness projects, including hotels, resorts, and club sports. Prim, S.A. was founded in 1870 and is headquartered in Móstoles, Spain.
How the Company Makes MoneyPRIM, S.A. generates revenue through the sale of its electronic components and systems, which are supplied to various industries including automotive, industrial automation, and consumer electronics. The company employs a diversified revenue model consisting of direct sales to original equipment manufacturers (OEMs), long-term supply contracts, and partnerships with other technology firms. Key revenue streams include product sales, licensing agreements for proprietary technologies, and after-sales services such as technical support and maintenance. Additionally, PRM benefits from strategic alliances with industry leaders, which not only expand its market reach but also enhance its product offerings, thereby contributing significantly to its earnings.

PRIM, S.A. Financial Statement Overview

Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
60
Neutral
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue233.15M216.51M197.25M168.51M147.32M
Gross Profit112.62M105.51M94.56M83.08M74.46M
EBITDA26.23M28.05M19.71M30.18M15.42M
Net Income10.92M12.67M8.39M17.42M6.92M
Balance Sheet
Total Assets190.28M200.10M184.99M179.85M163.64M
Cash, Cash Equivalents and Short-Term Investments13.75M13.25M14.94M36.54M35.16M
Total Debt18.50M25.48M22.07M19.07M20.45M
Total Liabilities61.34M74.28M65.28M58.38M51.90M
Stockholders Equity128.93M125.82M119.71M121.47M111.74M
Cash Flow
Free Cash Flow10.76M-41.38M13.87M19.56M
Operating Cash Flow22.11M-31.25M4.89M26.30M25.96M
Investing Cash Flow-7.59M-4.20M
Financing Cash Flow-11.32M30.37M3.11M

PRIM, S.A. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price13.30
Price Trends
50DMA
12.42
Positive
100DMA
11.79
Positive
200DMA
10.76
Positive
Market Momentum
MACD
0.33
Negative
RSI
61.65
Neutral
STOCH
85.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:PRM, the sentiment is Positive. The current price of 13.3 is above the 20-day moving average (MA) of 12.88, above the 50-day MA of 12.42, and above the 200-day MA of 10.76, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 61.65 is Neutral, neither overbought nor oversold. The STOCH value of 85.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:PRM.

PRIM, S.A. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
€225.42M15.913.17%
65
Neutral
694.53M17.0843.18%3.82%
64
Neutral
230.31M34.734.85%1.71%0.58%-30.60%
51
Neutral
205.14M-6.62-12.55%5.54%30.33%
48
Neutral
261.00M-48.18-2.02%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ES:PRM
PRIM, S.A.
13.30
3.24
32.19%
GB:0GWJ
Clinica Baviera
42.40
8.44
24.85%
GB:0RB1
LABORATORIO REIG JOFRE
2.85
0.16
5.95%
DE:ORN
Oryzon Genomics SA
3.12
1.30
71.43%
DE:A2T
Atrys Health SA
2.55
-0.53
-17.21%
ES:LAB
Labiana Health SA
4.06
1.56
62.40%

PRIM, S.A. Corporate Events

PRIM, S.A. Updates Syndication Pact Composition
Jun 19, 2025

PRIM, S.A. has announced an expansion and update to the composition of its Syndication Pact, originally formalized on May 15, 2019. This update, communicated by Jorge Prim Martinez, President of the Syndicate, reflects changes agreed upon during the Shareholders’ Assembly meeting held on May 19, 2025, and involves a detailed list of shareholders and their respective shares, totaling 3,162,648 shares or 18.56%.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 12, 2025